[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100518208":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":41,"responsibleParty":60,"collaborators":63,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":75,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":26,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":26,"overallStatus":43,"whyStopped":26,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"UConn Health","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Placebo capsule","PLACEBO_COMPARATOR","Gelatin capsules",[13],"Dietary Supplement: Placebo capsule",{"label":15,"type":16,"description":17,"interventionNames":18},"MitoQ capsule","EXPERIMENTAL","Capsules containing mitoquinone mesylate (MitoQ, 5 mg\u002Fcapsule) totaling 20 mg taken every day for 12 weeks.",[19],"Drug: Mitoquinone Mesylate",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Mitoquinone Mesylate","MitoQ given 20 mg per day for 12 weeks.",[15],null,{"type":28,"name":9,"description":29,"armGroupLabels":30,"otherNames":26},"DIETARY_SUPPLEMENT","Placebo capsule taken every day for 12 weeks.",[9],[32],{"name":33,"affiliation":34,"role":35},"Oh Sung Kwon, PhD","University of Connecticut","PRINCIPAL_INVESTIGATOR",[37],{"name":33,"role":38,"phone":39,"phoneExt":26,"email":40},"CONTACT","860-486-1120","ohsung.kwon@uconn.edu",[42],{"facility":5,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"RECRUITING","Farmington","Connecticut","06030","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-72.83204,41.71982,{"lat":53,"lon":52},[56],{"name":57,"role":38,"phone":58,"phoneExt":26,"email":59},"George Kuchel, MD","860-679-6796","kuchel@uchc.edu",{"type":35,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":34,"oldNameTitle":26,"oldOrganization":26},"Oh Sung Kwon","Assistant Professor",[64,67],{"name":65,"class":66},"National Institute on Aging (NIA)","NIH",{"name":34,"class":6},"100518208","phase-2-the-mito-frail-trial-effects-of-mitoq-on-vasodilation-mobility-and-cognitive-performance-in-frail-older-adults-100518208",false,"NCT06027554","The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults","Mito-Frail","Inclusion Criteria:\n\n* men and women aged 65-80 with a slow gait speed (0.4m\u002Fs based on a 4m walk) and\u002For mild cognitive impairment.\n* good cardiovascular health (not taking any blood pressure\u002Fflow\u002Fmetabolism altering medications)\n\nExclusion Criteria:\n\n* A vaccination in past two weeks\n* Recent acute infection three weeks prior to enrollment\n* Known immunodeficiency (including HIV infection, primary immunodeficiency, any history of chemotherapy or radiotherapy\n* Use of medicines during past 6 months known to alter immune response such as high- dose corticosteroids\n* Severe autoimmune disease requiring biological therapy\n* Major severe illness and\u002For Hospitalization in past 3 months\n* On warfarin or other medications that are considered a blood thinner\n* Recent fall or other conditions that will impair ability to complete and\u002For interpret mobility performance test\n* Known bleeding disorder\n* Any conditions that would impair the function to perform grip strength test\n* include advanced neurological disease, severe co-morbid disease, terminal illness with reduced life expectancy, severe disability, unintentional weight loss in last 12 months and participation in another study.\n* Diabetes patients requiring insulin (For reducing the risk that participants will have hypoglycemic episodes when fasting for study visits)\n* Baseline ECG QTc \\>450 ms in men and QTc \\>460 ms in women\n* Prior diagnosis of ventricular arrhythmia (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes)",true,"ALL","65 Years","80 Years",{"count":80,"type":81},60,"ESTIMATED","INTERVENTIONAL",[84],"PHASE2","The goal of this clinical trial is to test the effects of MitoQ supplementation in older adults and frail older adults with physical dysfunction and\u002For cognitive dysfunction. The main question\\[s\\] it aims to answer are:\n\n* To compare vascular function, oxidative stress levels, and physical and cognitive function among older adults and frail older adults with physical and cognitive dysfunction\n* To determine whether MitoQ supplementation has the potential to improve vascular function in central and cerebral vessels\n* To determine whether MitoQ supplementation can enhance physical and cognitive capabilities.",[87,88,89],"Frailty","Mild Cognitive Impairment","Aging","2026-01-08",{"date":92,"type":93},"2026-01-09","ACTUAL",{"date":95,"type":93},"2024-10-07",{"date":97,"type":81},"2028-02-01",{"name":5,"class":6},1]